ArticleBMC infectious diseases2026
Prevalence of nontuberculous mycobacteria isolates and pulmonary disease from respiratory tract samples in persons investigated for presumed tuberculosis from three West African countries, an analysis of three prospective cohort studies.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundIn West Africa, the isolation of nontuberculous mycobacteria (NTM) is increasingly reported among individuals evaluated for tuberculosis (TB). However, the clinical relevance of NTM detection from respiratory tract samples remains unclear, creating uncertainty for clinicians when NTM are identified. As a first step in addressing this gap, we aimed to estimate the prevalence of NTM isolation from mycobacterial cultures among individuals with presumed TB, regardless of TB treatment history, and determine the proportion who met international diagnostic criteria for NTM pulmonary disease (NTM-PD).
methodsWe analysed data from three prospective cohort studies conducted in Ghana, Nigeria, and Niger using a descriptive analysis. Sputum samples were collected from all individuals presenting with presumed TB for smear microscopy and culture; additionally, Xpert MTB/RIF testing was performed in Ghana and Niger. NTM species were identified using GenoType CM/AS and/or rrs/rpoB sequencing. Drug-susceptibility testing was performed with phenotypic and genotypic methods. Clinical data were extracted from medical records and structured questionnaires, and patients underwent chest radiography.
resultsOut of 9,981 symptomatic individuals screened, 938 were subjected to mycobacterial culture, of whom 99 (Ghana: 31; Nigeria: 42; Niger: 26) had at least one NTM isolate. The prevalence of NTM detection among mycobacterial cultures was 10.6% (95%CI: 8.7%-12.7%). The mean age was 51.6 years, with 61.6% males; 46.5% had a history of TB, and 27.3% were living with HIV. Among the 99 patients, the predominant symptoms were cough (82.8%), weight loss (56.3%), fever (47.5%), and dyspnoea (28.3%). Consolidation was observed on chest x-ray in 73.7% and cavitation in 46.5%. Common NTM species included M. intracellulare (34.3%), M. fortuitum (16.2%), and M. abscessus complex (10.1%). Most M. intracellulare and M. abscessus complex were susceptible to macrolides and aminoglycosides. Of the 49 patients with two or more sputum samples processed for culture at baseline and/or follow up, 15 (30.6%) met the diagnostic criteria for NTM-PD, with all patients exhibiting smear positivity, clinical symptoms, radiological abnormalities and repeated culture of the same NTM species. Mortality for patients who were classified as NTM-PD was 43%.
conclusionThese findings provide insights into the clinical relevance of NTM isolation in TB-endemic settings. Active TB should be excluded in all symptomatic patients, as should other possible explanations such as (post-TB) bronchiectasis with bacterial superinfection, Aspergillus infection) if infrastructure allows, before attributing the clinical presentation to NTM. Until more context-specific epidemiologic and clinical data become available, adherence to NTM-PD diagnostic criteria is recommended to guide appropriate clinical decision-making. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.